Dose-Dependent Cognitive Decline, Anxiety, and Locomotor Impairments Induced by Doxorubicin: Evidence from an Animal Model
Cognitive impairment and anxiety are common side effects of chemotherapy, particularly with the use of doxorubicin (DOX), known as “chemobrain”. This study aimed to examine the dose-dependent effects of DOX on cognitive decline, anxiety, and locomotor activity in healthy female Wistar rats. The rats...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-11-01
|
| Series: | Biology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-7737/13/11/939 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846154282645061632 |
|---|---|
| author | Ângela Amaro-Leal Ana I. Afonso Filipa Machado Liana Shvachiy Isabel Rocha Tiago F. Outeiro Vera Geraldes |
| author_facet | Ângela Amaro-Leal Ana I. Afonso Filipa Machado Liana Shvachiy Isabel Rocha Tiago F. Outeiro Vera Geraldes |
| author_sort | Ângela Amaro-Leal |
| collection | DOAJ |
| description | Cognitive impairment and anxiety are common side effects of chemotherapy, particularly with the use of doxorubicin (DOX), known as “chemobrain”. This study aimed to examine the dose-dependent effects of DOX on cognitive decline, anxiety, and locomotor activity in healthy female Wistar rats. The rats were divided into groups receiving low (2 mg/kg), intermediate (4 mg/kg), and high (5 mg/kg) doses of DOX for four weeks, alongside a control group. Behavioral tests, including open field, elevated plus maze, and Y-maze tests, assessed anxiety, locomotion, and cognitive performance, while brain tissue analysis evaluated neuroinflammation using markers such as GFAP and Iba-1. The results showed that all doses of DOX induced anxiety-like behavior, reduced locomotion, and caused neuroinflammation in the hippocampus, with more severe effects at higher doses. Notably, high-dose DOX also caused short-term memory deficits. These findings highlight the dose-dependent nature of DOX’s impact on behavior and cognition, suggesting that DOX plays a key role in the development of cognitive symptoms during chemotherapy. Further research is needed to understand the mechanisms behind these effects and to explore potential interventions. |
| format | Article |
| id | doaj-art-e041f1ae605c4b1e9ffd4f8121f5c13f |
| institution | Kabale University |
| issn | 2079-7737 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biology |
| spelling | doaj-art-e041f1ae605c4b1e9ffd4f8121f5c13f2024-11-26T17:52:32ZengMDPI AGBiology2079-77372024-11-01131193910.3390/biology13110939Dose-Dependent Cognitive Decline, Anxiety, and Locomotor Impairments Induced by Doxorubicin: Evidence from an Animal ModelÂngela Amaro-Leal0Ana I. Afonso1Filipa Machado2Liana Shvachiy3Isabel Rocha4Tiago F. Outeiro5Vera Geraldes6Egas Moniz Center for Interdisciplinary Research (CiiEM), Egas Moniz School of Health & Science, 2829-511 Almada, PortugalFaculdade de Medicina, Universidade de Lisboa, Av. Prof Egas Moniz, 1649-028 Lisbon, PortugalFaculdade de Medicina, Universidade de Lisboa, Av. Prof Egas Moniz, 1649-028 Lisbon, PortugalCentro Cardiovascular da Universidade de Lisboa, Faculdade de Medicina, Universidade de Lisboa, Av. Prof Egas Moniz, 1649-028 Lisbon, PortugalFaculdade de Medicina, Universidade de Lisboa, Av. Prof Egas Moniz, 1649-028 Lisbon, PortugalDepartment of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center Göttingen, 37073 Göttingen, GermanyFaculdade de Medicina, Universidade de Lisboa, Av. Prof Egas Moniz, 1649-028 Lisbon, PortugalCognitive impairment and anxiety are common side effects of chemotherapy, particularly with the use of doxorubicin (DOX), known as “chemobrain”. This study aimed to examine the dose-dependent effects of DOX on cognitive decline, anxiety, and locomotor activity in healthy female Wistar rats. The rats were divided into groups receiving low (2 mg/kg), intermediate (4 mg/kg), and high (5 mg/kg) doses of DOX for four weeks, alongside a control group. Behavioral tests, including open field, elevated plus maze, and Y-maze tests, assessed anxiety, locomotion, and cognitive performance, while brain tissue analysis evaluated neuroinflammation using markers such as GFAP and Iba-1. The results showed that all doses of DOX induced anxiety-like behavior, reduced locomotion, and caused neuroinflammation in the hippocampus, with more severe effects at higher doses. Notably, high-dose DOX also caused short-term memory deficits. These findings highlight the dose-dependent nature of DOX’s impact on behavior and cognition, suggesting that DOX plays a key role in the development of cognitive symptoms during chemotherapy. Further research is needed to understand the mechanisms behind these effects and to explore potential interventions.https://www.mdpi.com/2079-7737/13/11/939doxorubicinanxietychemotherapy-induced cognitive impairmentcognitive dysfunction |
| spellingShingle | Ângela Amaro-Leal Ana I. Afonso Filipa Machado Liana Shvachiy Isabel Rocha Tiago F. Outeiro Vera Geraldes Dose-Dependent Cognitive Decline, Anxiety, and Locomotor Impairments Induced by Doxorubicin: Evidence from an Animal Model Biology doxorubicin anxiety chemotherapy-induced cognitive impairment cognitive dysfunction |
| title | Dose-Dependent Cognitive Decline, Anxiety, and Locomotor Impairments Induced by Doxorubicin: Evidence from an Animal Model |
| title_full | Dose-Dependent Cognitive Decline, Anxiety, and Locomotor Impairments Induced by Doxorubicin: Evidence from an Animal Model |
| title_fullStr | Dose-Dependent Cognitive Decline, Anxiety, and Locomotor Impairments Induced by Doxorubicin: Evidence from an Animal Model |
| title_full_unstemmed | Dose-Dependent Cognitive Decline, Anxiety, and Locomotor Impairments Induced by Doxorubicin: Evidence from an Animal Model |
| title_short | Dose-Dependent Cognitive Decline, Anxiety, and Locomotor Impairments Induced by Doxorubicin: Evidence from an Animal Model |
| title_sort | dose dependent cognitive decline anxiety and locomotor impairments induced by doxorubicin evidence from an animal model |
| topic | doxorubicin anxiety chemotherapy-induced cognitive impairment cognitive dysfunction |
| url | https://www.mdpi.com/2079-7737/13/11/939 |
| work_keys_str_mv | AT angelaamaroleal dosedependentcognitivedeclineanxietyandlocomotorimpairmentsinducedbydoxorubicinevidencefromananimalmodel AT anaiafonso dosedependentcognitivedeclineanxietyandlocomotorimpairmentsinducedbydoxorubicinevidencefromananimalmodel AT filipamachado dosedependentcognitivedeclineanxietyandlocomotorimpairmentsinducedbydoxorubicinevidencefromananimalmodel AT lianashvachiy dosedependentcognitivedeclineanxietyandlocomotorimpairmentsinducedbydoxorubicinevidencefromananimalmodel AT isabelrocha dosedependentcognitivedeclineanxietyandlocomotorimpairmentsinducedbydoxorubicinevidencefromananimalmodel AT tiagofouteiro dosedependentcognitivedeclineanxietyandlocomotorimpairmentsinducedbydoxorubicinevidencefromananimalmodel AT verageraldes dosedependentcognitivedeclineanxietyandlocomotorimpairmentsinducedbydoxorubicinevidencefromananimalmodel |